OUR BUSINESS
ALZAI serves diverse healthcare stakeholders, offering tailored benefits to each group, with a primary focus on clinical trials companies.
Save cost and time through pre-screening subjects with ALZAI. Identifying quality candidates early, lowering screen-failure rates and significantly accelerating recruitment.
Enhance patient care by integrating seamless Alzheimer’s risk screening into regular primary care delivery, improving patient outcomes.
Public or Private, ALZAI enables substantial gains by enabling risk-mitigation, disease prevention, care optimization through risk-flagging and early detection.
Gain early insight into Alzheimer’s disease risk, enabling proactive healthcare management and lifestyle changes promoting longevity.
Save cost and time through pre-screening subjects with ALZAI. Identifying quality candidates early, lowering screen-failure rates and significantly accelerating recruitment.
Enhance patient care by integrating seamless Alzheimer’s risk screening into regular primary care delivery, improving patient outcomes.
Public or Private, ALZAI enables substantial gains by enabling risk-mitigation, disease prevention, care optimization through risk-flagging and early detection.
Gain early insight into Alzheimer’s disease risk, enabling proactive healthcare management and lifestyle changes promoting longevity.
For Clinical Trial Sponsors, Researchers and Service Companies
Addresses a key need in Alzheimer’s drug development, optimizing clinical trial efficiency and reduces costs.
Estimated investment in AD drug development programs 1
Cost per screening, Risk, Expense, and Delay-to-market 2
Timeline for trial recruitment
Ongoing AD trials as of 2023 with more in pre-clinical phases
Assessed drugs for the treatment of AD 3
Pharmaceutical Companies: Enhance drug development efficiency and success rates
Clinical Research Organizations (CROs): Streamline patient recruitment and optimization
Research Institutions & Sponsors: Improves trial design and participant selection
Regulatory: No significant burden, FDA 510(k) not required for implementation
Revenue Model: Licensing ALZAI solutions plus professional services for data integration and tuning
Immediate Commercialization: Ready for product development without lengthy approval processes
Estimated investment in AD drug development programs 1
Cost per screening, Risk, Expense, and Delay-to-market 2
Timeline for trial recruitment
Ongoing AD trials as of 2023 with more in pre-clinical phases
Assessed drugs for the treatment of AD 3
ALZAI’s innovative Pre-Screening solution saves both time and money by reducing screen failure rates through non-invasive analysis of common patient data, identifying high-quality candidates for screening, significantly accelerating recruitment efficiency.
vs.
Pre-Screening
Subjects for Non-Invasive Pre-Screening
(Exclusion Criteria, Med Record Review)
Pre-Screening
Screening
Subjects for Invasive Screening
(Neuro-Cog, Blood-Gen, Lumbar, MRI, PET)
Screening
Subjects for Selected Trial
14,500
Screening Failures
~88%
Screening Failure Rate
4,000
Screening Failures
~66%
Screening Failure Rate
|
Standard Trial Recruitment Process
|
ALZAI-inclusive Trial Recruitment Process
|
|---|---|
|
Subjects for Non-Invasive Pre-Screening
(Exclusion Criteria, Med Record Review) |
|
|
40,000
Pre-Screening |
Alzai Health
40,000 Pre-Screening |
|
Subjects for Invasive Screening
(Neuro-Cog, Blood-Gen, Lumbar, MRI, PET) |
|
|
16,500
Screening |
6,000
Screening |
|
Subjects for Selected Trial
|
|
|
2,000
|
28,000
|
|
SUMMARY
|
|
|
14,500
Screening Failures ~88% Screening Failure Rate |
4,000
Screening Failures ~66% Screening Failure Rate |
|
Subjects for Non-Invasive Pre-Screening
(Exclusion Criteria, Med Record Review) |
|
|---|---|
|
Standard Trial Recruitment Process
|
ALZAI-inclusive Trial Recruitment Process
|
|
40,000
Pre-Screening |
Alzai Health
40,000 Pre-Screening |
|
Subjects for Invasive Screening
(Neuro-Cog, Blood-Gen, Lumbar, MRI, PET) |
|
|---|---|
|
Standard Trial Recruitment Process
|
ALZAI-inclusive Trial Recruitment Process
|
|
16,500
Screening |
6,000
Screening |
|
Subjects for Selected Trial
|
|
|---|---|
|
Standard Trial Recruitment Process
|
ALZAI-inclusive Trial Recruitment Process
|
|
2,000
|
28,000
|
|
SUMMARY
|
|
|---|---|
|
14,500
Screening Failures ~88% Screening Failure Rate |
4,000
Screening Failures ~66% Screening Failure Rate |
Large Health Systems & Institutions
Diagnostic & Lab Services
Insurance Companies: Risk assessment & early detection to lower costs.
Regulatory: Moderate burden, 510(k) Clinical Decision Support Tool, ~24-month timeline
Business Models: Pay-per-screen & annual licensing
ALZAI is Changing the Future of Alzheimer’s Disease Screening!
Reduction in subjects developing AD with early intervention 1
Slower Disease Progression with therapeutic intervention 2
AD Diagnostic Market (2024) 3
CAGR Growth (2025-2030) 3
ALZAI enhances primary care with AI-driven, 100% non-invasive AD risk assessment enabling early diagnoses of patients in early disease states that are often missed and preventative intervention for pre-disease high-risk patients. Both resulting in better patient outcomes and cost savings.
vs.
Population over 60
Population living with Mild AD or MCI
Diagnosed
Mild AD & MCI
Undiagnosed Mild AD and MCI
Lost to timely diagnosis & intervention
17%
Mild Cases Identified
Unknown
80%
Mild Cases Identified
80%
Number of High-Risk Patients 1
|
Standard of Care
|
ALZAI-inclusive Care
|
|---|---|
|
Population Over 60
|
|
|
2,800,000
|
2,800,000
|
|
Population living with Mild AD or MCI
|
|
|
280,000
|
280,000
|
|
Diagnosed Mild AD & MCI
|
|
|
47,600
|
224,000
|
|
Undiagnosed Mild AD and MCI Lost to timely diagnosis & intervention
|
|
|
232,400
|
56,000
|
|
SUMMARY
|
|
|
17%
Mild Cases Identifed Unknown Number of High-Risk Patients |
80%
Mild Cases Identifed 80% Number of High-Risk Patients |
|
Population Over 60
|
|
|---|---|
|
STANDARD OF CARE
|
ALZAI-INCLUSIVE CARE
|
|
2,800,000
|
2,800,000
|
|
Population living with Mild AD or MCI
|
|
|---|---|
|
STANDARD OF CARE
|
ALZAI-INCLUSIVE CARE
|
|
280,000
|
280,000
|
|
Diagnosed Mild AD & MCI
|
|
|---|---|
|
STANDARD OF CARE
|
ALZAI-INCLUSIVE CARE
|
|
47,600
|
224,000
|
|
Undiagnosed Mild AD and MCI Lost to timely diagnosis & intervention
|
|
|---|---|
|
STANDARD OF CARE
|
ALZAI-INCLUSIVE CARE
|
|
232,400
|
56,000
|
|
SUMMARY
|
|
|---|---|
|
17%
Mild Cases Identifed Unknown Number of High-Risk Patients |
80%
Mild Cases Identifed 80% Number of High-Risk Patients |
AD: Alzheimer’s Disease MCI: Mild Cognitive Impairment
